Musclepharm Stock Fundamentals
MusclePharm fundamentals help investors to digest information that contributes to MusclePharm's financial success or failures. It also enables traders to predict the movement of MusclePharm Pink Sheet. The fundamental analysis module provides a way to measure MusclePharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MusclePharm pink sheet.
MusclePharm |
MusclePharm Company EBITDA Analysis
MusclePharm's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current MusclePharm EBITDA | (7.07 M) |
Most of MusclePharm's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MusclePharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, MusclePharm reported earnings before interest,tax, depreciation and amortization of (7.07 Million). This is 100.47% lower than that of the Food Products sector and 100.72% lower than that of the Consumer Staples industry. The ebitda for all United States stocks is 100.18% higher than that of the company.
MusclePharm Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining MusclePharm's current stock value. Our valuation model uses many indicators to compare MusclePharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MusclePharm competition to find correlations between indicators driving MusclePharm's intrinsic value. More Info.MusclePharm is rated top company in revenue category among its peers. It also is considered to be number one stock in ebitda category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the MusclePharm's earnings, one of the primary drivers of an investment's value.MusclePharm EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MusclePharm's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of MusclePharm could also be used in its relative valuation, which is a method of valuing MusclePharm by comparing valuation metrics of similar companies.MusclePharm is currently under evaluation in ebitda category among its peers.
MusclePharm Fundamentals
| Revenue | 50.04 M | |||
| EBITDA | (7.07 M) | |||
| Net Income | (12.87 M) | |||
| Total Debt | 10.71 M | |||
| Cash Flow From Operations | (8.04 M) | |||
| Number Of Employees | 21 | |||
| Total Asset | 11.21 M | |||
| Retained Earnings | (205.54 M) | |||
| Working Capital | (30.11 M) | |||
| Net Asset | 11.21 M |
About MusclePharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MusclePharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MusclePharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MusclePharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with MusclePharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MusclePharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MusclePharm will appreciate offsetting losses from the drop in the long position's value.Moving against MusclePharm Pink Sheet
| 0.87 | JXN-PA | Jackson Financial | PairCorr |
| 0.81 | HD | Home Depot | PairCorr |
| 0.78 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.71 | CSCO | Cisco Systems Sell-off Trend | PairCorr |
| 0.68 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
The ability to find closely correlated positions to MusclePharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MusclePharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MusclePharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MusclePharm to buy it.
The correlation of MusclePharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MusclePharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MusclePharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MusclePharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in MusclePharm Pink Sheet
If you are still planning to invest in MusclePharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MusclePharm's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |